Table 1.
Demographics and Clinic Characteristics of Patients With AON at Baseline
| Patients with AON | ||
| n | 84 | |
| Age (y) | 34.8 (29.3–42.7) | |
| Sex (female) | 65 (76%) | |
| Duration (d) | 9.0 (6.0–15.0) | |
| Etiology | Idiopathic: 20 (24%); MS: 26 (31%); CIS: 32 (38%); MOGAD: 6 (7%) |
|
| Affected eye (right) | 50 (59%) | |
| Corticosteroid therapy | IV high dose: 47 (55%); oral high dose: 19 (22%); oral low dose: 3 (4%); none: 16 (19%) | |
| Disease-modifying therapies baselinea | 16 (24%) | |
| Visual function affected eye | Baseline | Month 6 |
| HCVA (EDTRS, logMar) | 0.34 (0.08 to 0.86) | 0 (−0.06 to 0.07) |
| 2.5% LCVA (Sloan, # letters) | 0 (0 to 0) | 19 (3.5 to 28.5) |
| Color vision (HRR, # letters) | 21 (0 to 31.25) | 36 (32 to 36) |
| Visual fields (mean deviation) | −11.39 (−21.35 to −5.08) | −4.82 (−4.82 to −1.82) |
| VEP latencies (msec) | 173 (165 to 177) | 168 (159 to 178) |
| VEP amplitudes (mV) | 121 (61 to 149) | 136 (102 to 172) |
| EDSS | 2.0 (1.5 to 3.0) | 1.0 (0 to 1.5) |
| VFQ25 global | — | 92.3 (85.5 to 96) |
| VFQ25 + 10 items neuro-ophthalmology | — | 75.1 (63.1 to 84.2) |
Abbreviations: EDSS = Expanded Disability Status Scale; HCVA = high-contrast visual acuity using EDTRS charts; HRR = Hardy Rand and Rittler Pseudoisochromatic Plates; LCVA = low-contrast visual acuity using 2.5% contrast Sloan charts; VEP = visual evoked potential; VFQ25 = Visual Function Questionnaire.
Data are shown as mean and interquartile range (IQR) or number (percentage). Visual acuity refers to the affected eye.
a
DMDs: teriflunomide: 1 (6%), interferon-beta: 5 (32%), glatiramer acetate: 4 (25%), fingolimod: 1 (6%), dimethyl fumarate: 1 (6%), anti-CD20: 4 (25%).